{"id":80858,"date":"2022-09-21T21:35:00","date_gmt":"2022-09-21T14:35:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2022092121350080858"},"modified":"2022-09-22T22:17:37","modified_gmt":"2022-09-22T14:17:37","slug":"%e8%80%90%e7%ab%8b%e5%85%8bi-ii%e6%9c%9f%e4%b8%b4%e5%ba%8a%e7%a0%94%e7%a9%b6%e7%bb%93%e6%9e%9c%e5%9c%a8%e5%9b%bd%e9%99%85%e6%9d%83%e5%a8%81%e6%9c%9f%e5%88%8a%e3%80%8ajournal-of-hematology","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2022092121350080858","title":{"rendered":"\u8010\u7acb\u514b\u00aeI\/II\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u5728\u56fd\u9645\u6743\u5a01\u671f\u520a\u300aJournal of Hematology\uff06Oncology\u300b\u53d1\u8868\uff0c\u9a8c\u8bc1best-in-class\u6f5c\u529b"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e02<\/span>2022\u5e749\u670821\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u751f\u7269\u533b\u836f\u4f01\u4e1a-\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff0c\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b®<\/sup>\uff09\u6cbb\u7597\u8010\u836f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u7684I\u671f\u548cII\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u5df2\u4e8e\u8fd1\u671f\u5728\u56fd\u9645\u8457\u540d\u80bf\u7624\u5b66\u672f\u671f\u520aJournal of Hematology<\/i>\uff06<\/i>Oncology<\/i>\uff08\u4ee5\u4e0b\u7b80\u79f0\uff1aJHO<\/i>\u671f\u520a\uff09\u4e0a\u6b63\u5f0f\u53d1\u8868\uff0c\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u5176\u5728CML\u60a3\u8005\u4e2d\u7684\u6301\u4e45\u7597\u6548\u548c\u5b89\u5168\u6027\u3002<\/p>\n

\n<\/p><\/div>\n

JHO<\/i>\u671f\u520a\u662f\u5168\u7403\u8840\u6db2\u5b66\u548c\u80bf\u7624\u5b66\u9886\u57df\u7684\u9886\u5148\u520a\u7269\uff0c\u8be5\u671f\u520a\u53d1\u8868\u7684\u9876\u7ea7\u7814\u7a76\u5168\u65b9\u4f4d\u6db5\u76d6\u4e86\u8840\u6db2\u5b66\u548c\u80bf\u7624\u5b66\u9886\u57df\uff0c\u5176\u5f71\u54cd\u56e0\u5b50\u4e3a23.168[1]<\/sup>\u3002\u6b64\u6b21\u53d1\u8868\u5728\u8be5\u671f\u520a\u4e0a\u7684\u7814\u7a76\u9898\u4e3aOlverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial<\/i>[2]<\/sup>\u3002\u8010\u7acb\u514b®<\/sup>\u4e2d\u56fd\u4e34\u5e8a\u8bd5\u9a8c\u4e3b\u8981\u7814\u7a76\u8005\u3001\u5317\u4eac\u5927\u5b66\u8840\u6db2\u75c5\u7814\u7a76\u6240\u6240\u957f\u3001\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u8840\u6db2\u79d1\u4e3b\u4efb\u9ec4\u6653\u519b\u6559\u6388\u662f\u8be5\u6587\u7ae0\u7684\u901a\u8baf\u4f5c\u8005\uff1b\u8010\u7acb\u514b®<\/sup>\u4e2d\u56fd\u4e34\u5e8a\u8bd5\u9a8c\u4e3b\u8981\u7814\u7a76\u8005\u3001\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u8840\u6db2\u79d1\u526f\u4e3b\u4efb\u6c5f\u5029\u6559\u6388\u662f\u8be5\u6587\u7ae0\u7684\u7b2c\u4e00\u4f5c\u8005\u3002<\/p>\n

\u8be5\u7814\u7a76\u516c\u5e03\u4e86\u8010\u7acb\u514b®<\/sup>\u7528\u4e8e165\u4f8b\u524d\u671f\u63a5\u53d7\u8fc7\u591a\u7ebfTKI\u6cbb\u7597\u7684\u4e2d\u56fdCML\u60a3\u8005\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u3002\u53d7\u8bd5\u8005\u961f\u5217\u5305\u62ec\u4f34\u6709T315I\u7a81\u53d8\u7684TKI\u8010\u836fCML\u60a3\u8005\uff0c\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u8fd13\u5e74\u3002\u6570\u636e\u663e\u793a\uff0c\u5728CML\u6162\u6027\u671f\uff08CP\uff09\u60a3\u8005\u4e2d\uff0c\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\u548c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\u76843\u5e74\u7d2f\u79ef\u53cd\u5e94\u7387\u5206\u522b\u4e3a79%\u548c56%\uff1b\u5728CML\u52a0\u901f\u671f\uff08AP\uff09\u60a3\u8005\u4e2d\uff0c\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\u548c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\u76843\u5e74\u7d2f\u79ef\u53cd\u5e94\u7387\u5206\u522b\u4e3a47%\u548c45%\uff0c\u6b64\u5916\uff0c\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\uff0c\u7ec6\u80de\u9057\u4f20\u5b66\u548c\u5206\u5b50\u5b66\u53cd\u5e94\u7387\u4f1a\u8fdb\u4e00\u6b65\u589e\u52a0\u3002\u800c\u5728\u5b89\u5168\u6027\u65b9\u9762\uff0c\u5e38\u89c1\u975e\u8840\u6db2\u5b66\u4e0d\u826f\u4e8b\u4ef6\u4e3b\u8981\u4e3a\u76ae\u80a4\u8272\u7d20\u6c89\u7740\u3001\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\u7b49\uff0c\u5927\u591a\u4e3a1-2\u7ea7\uff1b\u8840\u6db2\u5b66\u4e0d\u826f\u4e8b\u4ef6\u5728\u6682\u65f6\u6682\u505c\u6cbb\u7597\u6216\u652f\u6301\u6cbb\u7597\u540e\u6d88\u9000\u3002\u4e0d\u826f\u4e8b\u4ef6\u591a\u4e3a\u53ef\u63a7\u5236\u548c\u53ef\u8010\u53d7\u3002\u7279\u522b\u662f\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\uff0c\u8840\u5c0f\u677f\u51cf\u5c11\u7b49\u526f\u4f5c\u7528\u6301\u7eed\u51cf\u5c11\u3002\u8fd9\u663e\u793a\u8010\u7acb\u514b®<\/sup>\u5728TKI\u8010\u836f\u7684CML-CP\u6216CML-AP\u60a3\u8005\u4e2d\u8010\u53d7\u826f\u597d\uff0c\u4e14\u7597\u6548\u7a33\u5b9a\u6301\u4e45\u3002\u6b64\u5916\uff0c\u8be5\u54c1\u79cd\u5bf9BCR-ABL1T315I<\/sup>\u7a81\u53d8\u4f53\u8868\u73b0\u51fa\u9ad8\u5ea6\u6d3b\u6027\uff0c\u5e76\u5728\u590d\u5408\u7a81\u53d8\u60a3\u8005\u4e2d\u5448\u73b0\u4ee4\u4eba\u9f13\u821e\u7684\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u800c\u8fd9\u90e8\u5206\u60a3\u8005\u76ee\u524d\u5c1a\u65e0\u6807\u51c6\u6cbb\u7597\u65b9\u6848\u3002<\/p>\n

CML\u662f\u4e00\u79cd\u4e0e\u767d\u7ec6\u80de\u6709\u5173\u7684\u6076\u6027\u80bf\u7624\u3002\u968f\u7740\u9776\u5411BCR-ABL\u7684\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08TKI\uff09\u7684\u4e0a\u5e02\uff0cCML\u7684\u6cbb\u7597\u65b9\u5f0f\u5f97\u4ee5\u9769\u65b0\u3002\u5c3d\u7ba1\u7b2c\u4e00\u4ee3\u548c\u7b2c\u4e8c\u4ee3TKI\u5bf9CML\u7684\u6cbb\u7597\u5177\u6709\u663e\u8457\u7684\u4e34\u5e8a\u6548\u76ca\uff0c\u4f46TKI\u8010\u836f\u4e00\u76f4\u662fCML\u6cbb\u7597\u7684\u4e3b\u8981\u6311\u6218\u3002<\/b>BCR-ABL\u6fc0\u9176\u533a\u7a81\u53d8\u662fTKI\u8010\u836f\u7684\u91cd\u8981\u673a\u5236\u4e4b\u4e00\uff0c\u5176\u4e2dT315I\u7a81\u53d8\u662f\u5e38\u89c1\u7684\u8010\u836f\u7a81\u53d8\u7c7b\u578b\u4e4b\u4e00\uff0c\u5728\u8010\u836fCML\u4e2d\u7684\u53d1\u751f\u7387\u53ef\u8fbe25%\u5de6\u53f3\u3002\u4f34\u6709T315I\u7a81\u53d8\u7684\u6162\u7c92\u60a3\u8005\u5bf9\u76ee\u524d\u6240\u6709\u4e00\u4ee3\u3001\u4e8c\u4ee3BCR-ABL\u6291\u5236\u5242\u5747\u8010\u836f\u3002\u4e34\u5e8a\u4e0a\u5bf9\u53ef\u5b89\u5168\u6709\u6548\u6cbb\u7597T315I\u7a81\u53d8CML\u6162\u7c92\u60a3\u8005\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u9700\u6c42\u5de8\u5927\u3002<\/p>\n

\u8010\u7acb\u514b®<\/sup>\u662f\u4e9a\u76db\u533b\u836f\u7814\u53d1\u7684\u6f5c\u5728\u540c\u7c7b\u6700\u4f73\uff08Best-in-class\uff09\u65b0\u836f\uff0c\u4e3a\u56fd\u5bb6"\u91cd\u5927\u65b0\u836f\u521b\u5236"\u4e13\u9879\u652f\u6301\u54c1\u79cd\u3002\u4f5c\u4e3a\u4e2d\u56fd\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u8010\u7acb\u514b®<\/sup>\u7684\u51fa\u73b0\u6253\u7834\u4e86\u4e2d\u56fd\u643aT315I\u7a81\u53d8\u8010\u836fCML\u60a3\u8005\u957f\u671f\u65e0\u836f\u53ef\u533b\u7684\u56f0\u5c40\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b®<\/sup>\u5df2\u83b7\u4e2d\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08CSCO\uff09\u6307\u5357\u548c\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u300a\u4e2d\u56fd\u80bf\u7624\u6574\u5408\u8bca\u6cbb\u6307\u5357\uff08CACA\uff09\u300b\u63a8\u8350\uff0c\u6cbb\u7597\u4f34\u6709T315I\u7a81\u53d8\u7684\u65e2\u5f80TKI\u8010\u836f\u6162\u7c92\u60a3\u8005\uff08CACA\u6307\u5357\u4ea6\u63a8\u8350\u8be5\u54c1\u79cd\u7528\u4e8e\u6cbb\u7597\u63a5\u53d7\u8fc72\u79cd\u4ee5\u4e0aTKI\u8010\u836f\u6216\u4e0d\u8010\u53d7\u7684\u6162\u7c92\u60a3\u8005\uff09\u3002<\/p>\n

\u800c\u5728\u5168\u7403\u5c42\u9762\uff0c\u5c3d\u7ba1\u6b64\u524d\u5df2\u6709\u53e6\u5916\u4e00\u6b3eBCR-ABL\u6291\u5236\u5242\u83b7\u6279\uff0c\u4f46\u56e0\u836f\u7269\u53ef\u53ca\u6027\u3001\u836f\u7269\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u7b49\u539f\u56e0\uff0c\u8010\u836fCML\u7684\u6cbb\u7597\u4ecd\u7136\u5b58\u5728\u672a\u88ab\u5b8c\u5168\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u3002\u6b63\u56e0\u5982\u6b64\uff0c\u8fd1\u5e74\u6765\u8be5\u836f\u7269\u7684\u4e34\u5e8a\u8fdb\u5c55\u4e0d\u65ad\u53d7\u5230\u5168\u7403\u8840\u6db2\u5b66\u754c\u7684\u5173\u6ce8\u3002\u81ea2018\u5e74\u8d77\uff0c\u8010\u7acb\u514b®<\/sup>\u7684\u4e34\u5e8a\u8fdb\u5c55\u8fde\u7eed\u56db\u5e74\u5165\u9009\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\uff0c\u5e76\u8363\u83b72019 ASH\u5e74\u4f1a"\u6700\u4f73\u7814\u7a76"\u7684\u63d0\u540d\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b®<\/sup>\u5df2\u5728\u7f8e\u56fd\u8fdb\u5165Ib\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u7528\u4e8e\u6cbb\u7597\u8010\u836fCML\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b®<\/sup>\u5171\u83b71\u9879\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u5feb\u901f\u901a\u9053\u8d44\u683c\u30013\u9879FDA\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u548c1\u9879\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u7684\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002<\/p>\n

\u9ec4\u6653\u519b\u6559\u6388\u8868\u793a\uff1a"\u4f5c\u4e3a\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u94bb\u7814\u8d85\u8fc730\u5e74\u7684\u4e2d\u56fd\u4e34\u5e8a\u533b\u751f\uff0c\u4e5f\u4f5c\u4e3a\u8010\u7acb\u514b®<\/sup>\u4e34\u5e8a\u8bd5\u9a8c\u7684\u4e3b\u8981\u7814\u7a76\u8005\uff0c\u6211\u5f88\u9ad8\u5174\u770b\u5230\u8010\u7acb\u514b®<\/sup>\u8fd9\u6b3e\u521b\u65b0\u836f\u7269\u7684\u4e34\u5e8a\u8fdb\u5c55\u5728JHO<\/i>\u671f\u520a\u4e0a\u53d1\u8868\uff0c\u8fd9\u518d\u6b21\u8bc1\u660e\u8010\u7acb\u514b®<\/sup>\u8fd9\u4e00\u4e2d\u56fd\u539f\u521b\u7684\u4ea7\u54c1\u6709\u671b\u4e3a\u5168\u7403CML\u6cbb\u7597\u9886\u57df\u5e26\u53bb\u4e2d\u56fd\u65b9\u6848\u3002\u5e0c\u671b\u6709\u8d8a\u6765\u8d8a\u591a\u50cf\u8010\u7acb\u514b®<\/sup>\u8fd9\u6837\u7684\u672c\u571f\u521b\u65b0\u836f\u6d8c\u73b0\uff0c\u7ed9\u5230\u66f4\u591a\u4e2d\u56fd\u4e34\u5e8a\u533b\u751f\u673a\u4f1a\u4e3b\u5bfc\u65b0\u836f\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5728\u8fd9\u4e00\u8fc7\u7a0b\u4e2d\u79ef\u7d2f\u4e2d\u56fd\u6570\u636e\u548c\u7ecf\u9a8c\u5e76\u8f6c\u5316\u4e3a\u5177\u6709\u56fd\u9645\u524d\u77bb\u6027\u7684\u5faa\u8bc1\u533b\u5b66\u6210\u679c\u5bf9\u5916\u53d1\u8868\uff0c\u6700\u7ec8\u63d0\u5347\u4e2d\u56fd\u5728\u5168\u7403\u7684\u56fd\u9645\u5b66\u672f\u5f71\u54cd\u529b\u3002"<\/p>\n

\u6c5f\u5029\u6559\u6388\u8868\u793a\uff1a"\u76ee\u524d\uff0cCML\u60a3\u8005\u4e2d\u670920-30%\u4f1a\u5bf9\u73b0\u6709TKI\u8010\u836f\u6216\u4e0d\u8010\u53d7\uff0c\u4ece\u800c\u5bfc\u81f4\u75be\u75c5\u8fdb\u5c55\uff0c\u5176\u4e2d\uff0c\u8bb8\u591a\u60a3\u8005\u5728\u8f6c\u6362\u7528\u7b2c\u4e8c\u79cd\u6216\u7b2c\u4e09\u79cdTKI\u540e\u4f1a\u56e0\u65b0\u7684\u7a81\u53d8\u6216\u5176\u4ed6\u5e76\u53d1\u75c7\u800c\u672a\u80fd\u8fbe\u5230\u9884\u671f\u91cc\u7a0b\u7891\u76ee\u6807\u5bfc\u81f4\u6cbb\u7597\u5931\u8d25\u3002\u53ef\u4ee5\u8bf4\uff0cTKI\u8010\u836f\u662fCML\u6cbb\u7597\u5168\u7403\u6027\u7684\u6311\u6218\u3002\u6b64\u6b21\u53d1\u8868\u5728JHO<\/i>\u671f\u520a\u4e0a\u7684\u6570\u636e\u663e\u793a\uff0c\u8010\u7acb\u514b®<\/sup>\u5bf9\u4e8eCML\u5177\u6709\u826f\u597d\u7684\u7597\u6548\u5e76\u80fd\u591f\u6709\u6548\u514b\u670dT315I\u7a81\u53d8\uff0c\u540c\u65f6\u5bf9\u76ee\u524d\u5c1a\u65e0\u6709\u6548\u6cbb\u7597\u65b9\u6848\u7684BCR-ABL\u6fc0\u9176\u7ed3\u6784\u57df\u590d\u5408\u7a81\u53d8\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002\u8fd9\u4ee3\u8868\u8010\u7acb\u514b®<\/sup>\u662f\u4e00\u79cd\u6781\u5bcc\u6f5c\u529b\u7684CML\u6cbb\u7597\u836f\u7269\u3002"<\/p>\n

\u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a"\u8010\u7acb\u514b®<\/sup>\u662f\u5177\u6709"best-in-class"\u6f5c\u529b\u7684\u539f\u521b1\u7c7b\u65b0\u836f\uff0c\u5176\u4e34\u5e8a\u5f00\u53d1\u662f\u4e9a\u76db\u533b\u836f\u5168\u7403\u521b\u65b0\u6218\u7565\u7684\u8df5\u884c\u3002\u6b64\u6b21\u8010\u7acb\u514b®<\/sup>\u7684I\/II\u671f\u4e34\u5e8a\u8fdb\u5c55\u8363\u767bJournal of Hematology<\/i>\uff06<\/i>Oncology<\/i>\uff0c\u65e2\u4f53\u73b0\u4e86\u8be5\u54c1\u79cd\u5728\u5168\u7403\u8010\u836fCML\u9886\u57df\u7684\u6cbb\u7597\u6f5c\u529b\uff0c\u66f4\u4ee3\u8868\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u6218\u7565\u518d\u65a9\u4f73\u7ee9\u3002\u6211\u4eec\u8feb\u5207\u5730\u671f\u5f85\u8010\u7acb\u514b®<\/sup>\u80fd\u4ee5\u4e2d\u56fd\u4e3a\u8d77\u70b9\uff0c\u4e3a\u5168\u7403\u8010\u836fCML\u60a3\u8005\u5e26\u53bb\u4e00\u79cd\u7597\u6548\u786e\u5207\u3001\u5b89\u5168\u6027\u66f4\u4f73\u7684\u6cbb\u7597\u65b9\u6848\u3002\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u575a\u5b88\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42’\u7684\u4f7f\u547d\uff0c\u52a0\u5feb\u516c\u53f8\u5728\u7814\u54c1\u79cd\u5728\u5168\u7403\u5c42\u9762\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u9020\u798f\u60a3\u8005\u3002"<\/p>\n

\u6b64\u6b21\u8010\u7acb\u514b®<\/sup>\u767b\u4e0aJournal of Hematology & Oncology<\/i>\u7684\u7814\u7a76\u8981\u70b9\u5982\u4e0b\uff1a<\/p>\n

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial<\/b><\/p>\n

\u5965\u96f7\u5df4\u66ff\u5c3c —<\/span> \u5bf9<\/b>T315I<\/b>\u7a81\u53d8\u6162\u6027\u9ad3<\/b>\u6027<\/b>\u767d\u8840\u75c5\u60a3\u8005\u5b89\u5168\u6709\u6548\u7684\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff1a\u4e00\u9879\u5f00\u653e\u3001\u591a\u4e2d\u5fc3\u7684<\/b>I\/II<\/b>\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c<\/b><\/p>\n

\u7814\u7a76\u65b9\u6cd5<\/u><\/b>\uff1a<\/b><\/p>\n

    \n
  • \u8fd9\u662f\u4e00\u9879\u5f00\u653e\u6807\u7b7e\u7684\uff0c\u591a\u4e2d\u5fc3I\/II\u671f\u7814\u7a76\u3002<\/li>\n
  • I\u671f\u7814\u7a76\u90e8\u5206\u4f7f\u7528\u6807\u51c6\u8bbe\u8ba1\u7684"3+3"\u5242\u91cf\u9012\u589e\u548c\u5242\u91cf\u6269\u5c55\uff0c\u5965\u96f7\u5df4\u66ff\u5c3c\u91c7\u7528\u53e3\u670d\u3001\u9694\u65e5\u7ed9\u836f\u300128\u5929\u4e3a\u4e00\u4e2a\u5468\u671f\uff0c\u5171\u6709\u4ece1\u81f360 mg\u768411\u4e2a\u5242\u91cf\u7ec4\u3002I\u671f\u7814\u7a76\u7684\u4e3b\u8981\u7814\u7a76\u7ec8\u70b9\u662fII\u671f\u7814\u7a76\u63a8\u8350\u5242\u91cf\uff08RP2D\uff09\u3002<\/li>\n
  • II\u671f\u7814\u7a76\u90e8\u5206\u5728RP2D\u4e0b\u8bc4\u4f30\u5965\u96f7\u5df4\u66ff\u5c3c\u5728T315I\u7a81\u53d8CML-CP\u548cCML-AP\u60a3\u8005\u4e2d\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002II\u671f\u7814\u7a76\u7684\u4e3b\u8981\u7814\u7a76\u7ec8\u70b9\u662f\u5965\u96f7\u5df4\u66ff\u5c3c\u5728CML-CP\u60a3\u8005\u7684\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\uff08MCyR\uff09\u548cCML-AP\u60a3\u8005\u4e2d\u7684\u4e3b\u8981\u8840\u6db2\u5b66\u53cd\u5e94\uff08MaHR\uff09\u3002<\/li>\n<\/ul>\n

    \u5165\u7ec4\u60a3\u8005\u7279\u5f81<\/u><\/b><\/p>\n

      \n
    • 2016\u5e7410\u670826\u65e5\u81f32019\u5e7410\u670808\u65e5\u671f\u95f4\uff0c\u7814\u7a76\u5171\u5165\u7ec4165\u4f8b\u60a3\u8005\u3002\u5176\u4e2d\u5305\u542b127\u4f8bCML-CP\u60a3\u8005\u548c38\u4f8bCML-AP\u60a3\u8005\u300266.7%\uff08110\u4f8b\uff09\u7684\u60a3\u8005\u4e3a\u7537\u6027\u3002\u4e2d\u4f4d\u5e74\u9f84\u4e3a42\uff08\u8303\u56f4\uff1a20~74\uff09\u5c81\u3002\u60a3\u8005\u4ece\u8bca\u65ad\u4e3aCML\u5230\u63a5\u53d7\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u7684\u4e2d\u4f4d\u65f6\u95f4\u4e3a5.7\uff080.3~23.2\uff09\u5e74\u3002<\/li>\n
    • \u8d85\u8fc780%\u7684\u60a3\u8005\u65e2\u5f80\u63a5\u53d7\u8fc72\u79cd\u53ca\u4ee5\u4e0aTKI\u6cbb\u7597\uff1a\u5176\u4e2d54.5%\uff0890\u4f8b\uff09\u60a3\u8005\u65e2\u5f80\u63a5\u53d7\u8fc72\u79cdTKI\u6cbb\u7597\uff1b27.3%\uff0845\u4f8b\uff09\u81f3\u5c11\u63a5\u53d7\u8fc73\u79cdTKI\u6cbb\u7597\u3002<\/li>\n
    • Sanger\u6d4b\u5e8f\u7ed3\u679c\u663e\u793a\uff0c61.8%\u7684\u60a3\u8005\u4f34\u6709T315I\u5355\u4f4d\u70b9\u7a81\u53d8\uff0c15.2%\u7684\u60a3\u8005\u4f34\u6709T315I\u53ca\u9644\u52a0\u7a81\u53d8\uff0c8.5%\u7684\u60a3\u8005\u4f34\u6709T315I\u4ee5\u5916\u7684\u5176\u4ed6\u7a81\u53d8\u3002<\/li>\n<\/ul>\n

      I<\/u><\/b>\u671f\u7814\u7a76<\/u><\/b><\/p>\n

        \n
      • 2016\u5e7410\u670826\u65e5\u81f32018\u5e7412\u670812\u65e5\u671f\u95f4\uff0c\u5171\u6709101\u4f8bTKI\u8010\u836fCML\u60a3\u8005\u5165\u7ec4\u2160\u671f\u7814\u7a76\u3002\u5176\u4e2d\uff0c86\u4f8b\u60a3\u8005\u4e3aCML-CP\uff0c15\u4f8b\u4e3aCML-AP\u3002<\/li>\n
      • \u572811\u4e2a\u5242\u91cf\u7ec4\uff081~60 mg QOD\uff0c28\u5929\u4e3a\u4e00\u4e2a\u5468\u671f\uff09\u4e2d\uff0c60 mg\u961f\u5217\u4e2d\u89c2\u5bdf\u5230\u5242\u91cf\u9650\u5236\u6027\u6bd2\u6027\uff08DLT\uff09\uff0c\u6700\u5927\u8010\u53d7\u5242\u91cf\uff08MTD\uff09\u4e3a50 mg\u3002\u57fa\u4e8e\u521d\u6b65\u5b89\u5168\u6027\u548c\u7597\u6548\u7ed3\u679c\uff0c\u5c06RP2D\u786e\u5b9a\u4e3a40 mg QOD\u3002<\/li>\n<\/ul>\n

        II<\/u><\/b>\u671f\u7814\u7a76<\/u><\/b><\/p>\n

          \n
        • \u786e\u5b9aRP2D\u540e\uff0c\u5728\u4e2d\u56fd10\u5bb6\u7814\u7a76\u4e2d\u5fc3\u542f\u52a8\u4e862\u9879\u5173\u952e\u6027\u7814\u7a76\uff0c\u5206\u522b\u5165\u7ec4\u4e8641\u4f8bT315I\u7a81\u53d8CML-CP\u60a3\u8005\u548c23\u4f8bT315I\u7a81\u53d8CML-AP\u60a3\u8005\uff0c\u5176\u4e2d\u8d85\u8fc760%\u7684\u60a3\u8005\u63a5\u53d7\u4e86\u4e8c\u7ebf\u6cbb\u7597\u3002<\/li>\n
        • \u622a\u81f32021\u5e749\u670830\u65e5\uff0c\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u4e3a34.3\uff084.8~58.6\uff09\u4e2a\u6708\uff0c\u4ecd\u670969.0%\uff08114\u4f8b\uff09\u7684\u60a3\u8005\u5728\u63a5\u53d7\u5965\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7597\u3002<\/li>\n<\/ul>\n

          \u5b89<\/span>\u5168\u6027<\/b><\/p>\n

            \n
          • \u4e2d\u4f4d\u6cbb\u7597\u6301\u7eed\u65f6\u95f4\u4e3a30.7\uff081.2~58.6\uff09\u4e2a\u6708\u3002\u5e38\u89c1\u7684\u975e\u8840\u6db2\u5b66TRAE\u662f\u76ae\u80a4\u8272\u7d20\u6c89\u7740\uff0c\u89c1\u4e8e139\u4f8b\uff0884.2%\uff09\u60a3\u8005\uff0c\u5176\u6b21\u662f\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\uff0857.6%\uff09\u3001\u86cb\u767d\u5c3f\uff0850.9%\uff09\u3001\u9ad8\u80c6\u7ea2\u7d20\u8840\u75c7\uff0841.8%\uff09\u3001\u4f4e\u9499\u8840\u75c7\uff0838.8%\uff09\u548c\u809d\u8f6c\u6c28\u9176\u5347\u9ad8\uff0835.8%\uff09\u3002<\/li>\n
          • 3\/4\u7ea7\u8840\u6db2\u5b66TRAE\u5305\u62ec\u8840\u5c0f\u677f\u51cf\u5c11\u75c7(51.5%)\u3001\u8d2b\u8840\uff0823.0%\uff09\u3001\u767d\u7ec6\u80de\u51cf\u5c11\uff0820.6%\uff09\u3001\u4e2d\u6027\u7c92\u7ec6\u80de\u51cf\u5c11\u75c7(11.5%)\u3002\u9aa8\u9ad3\u6291\u5236\u591a\u53d1\u751f\u4e8e\u65e9\u671f\u3002\u5927\u591a\u6570TRAE\u5728\u6682\u505c\u6cbb\u7597\u6216\u652f\u6301\u6cbb\u7597\uff08\u5305\u62ec\u8840\u5c0f\u677f\u6216\u7ea2\u7ec6\u80de\u8f93\u6ce8\u6216\u5242\u91cf\u8c03\u6574\uff09\u540e\u6d88\u9000\u3002<\/li>\n
          • 53\u4f8b\uff0832.1%\uff09\u60a3\u8005\u5728\u6cbb\u7597\u671f\u95f4\u89c2\u5bdf\u5230\u5965\u96f7\u5df4\u66ff\u5c3c\u76f8\u5173\u7684\u5fc3\u8840\u7ba1\u4e8b\u4ef6\uff08CVEs\uff09\uff0c\u4e3b\u8981\u5305\u62ec\u9ad8\u8840\u538b\uff0813.3%\uff09\u3001\u5fc3\u5305\u79ef\u6db2\uff088.5%\uff09\u7b49\uff0c\u5176\u4e2d3\/4\u7ea7CVEs\u536011.5%\uff0c\u52a8\u8109\u95ed\u585e\u53ca\u9759\u8109\u8840\u6813\u6813\u585e\u4e8b\u4ef6\u53d1\u751f\u7387\u4e3a5%\uff0c\u8fdc\u4f4e\u4e8e\u5168\u7403\u9996\u4e2a\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u62a5\u9053\u768431%\u3002<\/li>\n
          • \u9664\u76ae\u80a4\u8272\u7d20\u6c89\u7740\u548c\u86cb\u767d\u5c3f\u5916\uff0cTRAE\u7684\u53d1\u751f\u7387\u5728\u968f\u8bbf\u671f\u95f4\u968f\u65f6\u95f4\u9010\u6b65\u4e0b\u964d\u3002\u672a\u89c2\u5bdf\u5230\u6301\u7eed\u6027\u86cb\u767d\u5c3f\u60a3\u8005\u7684\u80be\u529f\u80fd\u4e0b\u964d\u3002\u53d1\u751f\u7387\u5927\u4e8e1%\u7684\u4e25\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAE\uff09\u5305\u62ec\u8840\u5c0f\u677f\u51cf\u5c11(9.0%)\u3001\u8d2b\u8840(6.0%),\u3001\u80ba\u708e(3.0%)\u3001\u53d1\u70ed\u6216\u623f\u98a4(\u54042.0%);\u4ee5\u53ca\u6025\u6027\u5fc3\u808c\u6897\u6b7b\u3001\u80c6\u77f3\u75c7\u3001\u5fc3\u5305\u79ef\u6db2\u3001\u4e0a\u547c\u5438\u9053\u611f\u67d3\u548c\u5c3f\u8def\u611f\u67d3\uff08\u54041%\uff09\u3002\u5927\u591a\u6570SAE\u5728\u6682\u65f6\u6682\u505c\u6cbb\u7597\u6216\u964d\u4f4e\u5242\u91cf\u540e\u6d88\u9000\u3002<\/li>\n<\/ul>\n

            \u7597<\/span>\u6548<\/b><\/p>\n

            Efficacy<\/b><\/p>\n

              \n
            • \u5728CML-CP\u60a3\u8005\u4e2d\uff0c\u81ea\u5f00\u59cb\u63a5\u53d7\u6709\u6548\u5242\u91cf\uff08\u226530 mg QOD\uff09\u540e\uff0c126\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u7684\u4e2d\u4f4d\u968f\u8bbf\u671f\u4e3a37\uff087~58\uff09\u4e2a\u6708\u3002100%\u60a3\u8005\u8fbe\u5230\u5b8c\u5168\u8840\u6db2\u5b66\u53cd\u5e94\uff08CHR\uff09\u3002MCyR\u548cCCyR\u5206\u522b\u4e3a79.3%\u548c69.4%\u300255.6%\u60a3\u8005\u8fbe\u5230\u6df1\u5ea6\u5206\u5b50\u751f\u7269\u5b66\u53cd\u5e94\uff08MMR)\uff0c44.4%\u7684\u60a3\u8005\u8fbe\u5230MR4.0<\/sup>\uff0c38.9%\u8fbe\u5230MR4.5<\/sup>\u3002\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\uff0c\u7ec6\u80de\u9057\u4f20\u5b66\u548c\u5206\u5b50\u5b66\u53cd\u5e94\u7387\u4f1a\u8fdb\u4e00\u6b65\u589e\u52a0\uff0cMCyR\u3001CCyR\u3001MMR\u3001MR4.0<\/sup>\u548cMR4.5<\/sup>\u7684\u7d2f\u79ef3\u5e74\u53d1\u751f\u7387\u5206\u522b\u4e3a78.6%\u300169.0%\u300155.9%\u300143.5%\u548c38.6%\u30023\u5e74\u65e0\u8fdb\u5c55\u751f\u5b58\u7387\uff08PFS\uff09\u548c\u603b\u751f\u5b58\u7387\uff08OS\uff09\u5206\u522b\u4e3a92.0%\u548c94.0%\u3002<\/li>\n
            • \u5728CML-AP\u60a3\u8005\u4e2d\uff0c\u81ea\u5f00\u59cb\u63a5\u53d7\u6709\u6548\u5242\u91cf\u540e\uff0c38\u4f8b\u53ef\u8bc4\u4f30\u60a3\u8005\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u4e3a27\uff085~56\uff09\u4e2a\u6708\u300278.4%\u7684\u60a3\u8005\u8fbe\u5230MaHR\uff1b73%\u7684\u60a3\u8005\u8fbe\u5230CHR\uff1bMCyR\u548cCCyR\u7684\u53d1\u751f\u7387\u5747\u4e3a47.4%\u3002\u5206\u522b\u670944.7%\u548c36.8%\u7684\u60a3\u8005\u8fbe\u5230MMR\u548cMR4.0<\/sup>\uff0c34.2%\u60a3\u8005\u8fbe\u5230MR4.5<\/sup>\u3002\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\uff0c\u7ec6\u80de\u9057\u4f20\u5b66\u548c\u5206\u5b50\u5b66\u53cd\u5e94\u7387\u4e5f\u8fdb\u4e00\u6b65\u589e\u52a0\uff0c\u8fbe\u5230MCyR\u3001CCyR\u3001MMR\u3001MR4.0<\/sup>\u548cMR4.5<\/sup>\u76843\u5e74\u7d2f\u79ef\u53d1\u751f\u7387\u5206\u522b\u4e3a47.4%\u300147.4%\u300144.7%\u300139.3%\u548c32.1%\uff0c3\u5e74PFS\u7387\u548cOS\u7387\u5206\u522b\u4e3a60.0%\u548c71.0%\u3002<\/li>\n<\/ul>\n

              \u7814\u7a76\u7ed3\u8bba<\/u><\/b><\/p>\n

              Conclusions<\/u><\/b><\/p>\n

                \n
              • \u5965\u96f7\u5df4\u66ff\u5c3c\u5728TKI\u8010\u836f\u7684CML-CP\u6216CML-AP\u60a3\u8005\u4e2d\u8010\u53d7\u826f\u597d\uff0c\u4e14\u7597\u6548\u7a33\u5b9a\u6301\u4e45\uff1b\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u8be5\u54c1\u79cd\u5bf9BCR-ABL1T315I<\/sup>\u7a81\u53d8\u4f53\u8868\u73b0\u51fa\u9ad8\u5ea6\u6d3b\u6027\uff0c\u5e76\u5728\u590d\u5408\u7a81\u53d8\u60a3\u8005\u4e2d\u5448\u73b0\u4ee4\u4eba\u9f13\u821e\u7684\u6297\u80bf\u7624\u6d3b\u6027\u3002<\/li>\n<\/ul>\n
                \n\n\n\n\n\n
                \n

                \u53c2\u8003\u8d44\u6599<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

                \n

                1.  2-Year Impact Factor (2021) as released by ClarivateTM<\/sup><\/span><\/p>\n<\/td>\n<\/tr>\n

                \n

                2.  Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol. Aug 18 2022;15(1):113. doi:10.1186\/s13045-022-01334-z<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

                \u5173\u4e8e\u4e9a\u76db\u533b\u836f<\/b><\/p>\n

                \u4e9a\u76db\u533b\u836f\u662f\u4e00\u5bb6\u7acb\u8db3\u4e2d\u56fd\u3001\u9762\u5411\u5168\u7403\u7684\u751f\u7269\u533b\u836f\u4f01\u4e1a\uff0c\u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u7684\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u30022019\u5e7410\u670828\u65e5\uff0c\u4e9a\u76db\u533b\u836f\u5728\u9999\u6e2f\u8054\u4ea4\u6240\u4e3b\u677f\u6302\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u7801\uff1a6855.HK\u3002<\/p>\n

                \u4e9a\u76db\u533b\u836f\u62e5\u6709\u81ea\u4e3b\u6784\u5efa\u7684\u86cb\u767d-\u86cb\u767d\u76f8\u4e92\u4f5c\u7528\u9776\u5411\u836f\u7269\u8bbe\u8ba1\u5e73\u53f0\uff0c\u5904\u4e8e\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u65b0\u836f\u7814\u53d1\u7684\u5168\u7403\u6700\u524d\u6cbf\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u62e5\u67099\u4e2a\u5df2\u8fdb\u5165\u4e34\u5e8a\u5f00\u53d1\u9636\u6bb5\u76841\u7c7b\u5c0f\u5206\u5b50\u65b0\u836f\u4ea7\u54c1\u7ba1\u7ebf\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u3001IAP \u6216MDM2-p53 \u7b49\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u7684\u6291\u5236\u5242\uff1b\u65b0\u4e00\u4ee3\u9488\u5bf9\u764c\u75c7\u6cbb\u7597\u4e2d\u51fa\u73b0\u7684\u6fc0\u9176\u7a81\u53d8\u4f53\u7684\u6291\u5236\u5242\u7b49\uff0c\u4e3a\u5168\u7403\u552f\u4e00\u5728\u7ec6\u80de\u51cb\u4ea1\u901a\u8def\u5173\u952e\u86cb\u767d\u9886\u57df\u5747\u6709\u4e34\u5e8a\u5f00\u53d1\u54c1\u79cd\u7684\u521b\u65b0\u516c\u53f8\u3002\u76ee\u524d\u516c\u53f8\u6b63\u5728\u4e2d\u56fd\u3001\u7f8e\u56fd\u3001\u6fb3\u5927\u5229\u4e9a\u53ca\u6b27\u6d32\u5f00\u5c5550\u591a\u9879I\/II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u3002\u7528\u4e8e\u6cbb\u7597\u8010\u836f\u6027\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\u7684\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b®<\/sup>\uff09\u66fe\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u65b0\u836f\u5ba1\u8bc4\u4e2d\u5fc3\uff08CDE\uff09\u7eb3\u5165\u4f18\u5148\u5ba1\u8bc4\u548c\u7a81\u7834\u6027\u6cbb\u7597\u54c1\u79cd\uff0c\u5e76\u5df2\u5728\u4e2d\u56fd\u83b7\u6279\uff0c\u662f\u516c\u53f8\u7684\u9996\u4e2a\u4e0a\u5e02\u54c1\u79cd\u3002\u8be5\u54c1\u79cd\u8fd8\u83b7\u5f97\u4e86\u7f8e\u56fdFDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u3001\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3001\u4ee5\u53ca\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002\u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f8\u5171\u67094\u4e2a\u5728\u7814\u65b0\u836f\u83b7\u5f9715\u9879FDA\u548c1\u9879\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\uff0c2\u9879FDA\u5feb\u901f\u901a\u9053\u8d44\u683c\u4ee5\u53ca2\u9879FDA\u513f\u7ae5\u7f55\u89c1\u75c5\u8d44\u683c\u8ba4\u8bc1\u3002\u516c\u53f8\u5148\u540e\u627f\u62c5\u591a\u9879\u56fd\u5bb6\u79d1\u6280\u91cd\u5927\u4e13\u9879\uff0c\u5176\u4e2d"\u91cd\u5927\u65b0\u836f\u521b\u5236"\u4e13\u98795\u9879\uff0c\u5305\u62ec1\u9879"\u4f01\u4e1a\u521b\u65b0\u836f\u7269\u5b75\u5316\u57fa\u5730"\u53ca4\u9879"\u521b\u65b0\u836f\u7269\u7814\u53d1"\uff0c\u53e6\u5916\u627f\u62c5"\u91cd\u5927\u4f20\u67d3\u75c5\u9632\u6cbb"\u4e13\u98791\u9879\u3002<\/p>\n

                \u51ed\u501f\u5f3a\u5927\u7684\u7814\u53d1\u80fd\u529b\uff0c\u4e9a\u76db\u533b\u836f\u5df2\u5728\u5168\u7403\u8303\u56f4\u5185\u8fdb\u884c\u77e5\u8bc6\u4ea7\u6743\u5e03\u5c40\uff0c\u5e76\u4e0eUNITY\u3001MD Anderson\u3001\u6885\u5965\u533b\u5b66\u4e2d\u5fc3\u548cDana-Farber\u764c\u75c7\u7814\u7a76\u6240\u3001\u9ed8\u6c99\u4e1c\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f89\u745e\u7b49\u9886\u5148\u7684\u751f\u7269\u6280\u672f\u53ca\u533b\u836f\u516c\u53f8\u3001\u5b66\u672f\u673a\u6784\u8fbe\u6210\u5168\u7403\u5408\u4f5c\u5173\u7cfb\u3002\u516c\u53f8\u5df2\u5efa\u7acb\u4e00\u652f\u5177\u6709\u4e30\u5bcc\u7684\u539f\u521b\u65b0\u836f\u7814\u53d1\u4e0e\u4e34\u5e8a\u5f00\u53d1\u7ecf\u9a8c\u7684\u56fd\u9645\u5316\u4eba\u624d\u56e2\u961f\uff0c\u540c\u65f6\uff0c\u516c\u53f8\u6b63\u5728\u9ad8\u6807\u51c6\u6253\u9020\u540e\u671f\u7684\u5546\u4e1a\u5316\u751f\u4ea7\u53ca\u5e02\u573a\u8425\u9500\u56e2\u961f\u3002\u4e9a\u76db\u533b\u836f\u5c06\u4e0d\u65ad\u63d0\u9ad8\u7814\u53d1\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u8fdb\u516c\u53f8\u4ea7\u54c1\u7ba1\u7ebf\u7684\u4e34\u5e8a\u5f00\u53d1\u8fdb\u5ea6\uff0c\u771f\u6b63\u8df5\u884c"\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42"\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n

                \u524d\u77bb\u6027\u58f0\u660e<\/b><\/p>\n

                \u672c\u6587\u6240\u4f5c\u51fa\u7684\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4e0e\u672c\u6587\u4f5c\u51fa\u8be5\u9648\u8ff0\u5f53\u65e5\u7684\u4e8b\u4ef6\u6216\u8d44\u6599\u6709\u5173\u3002\u9664\u6cd5\u5f8b\u89c4\u5b9a\u5916\uff0c\u4e8e\u4f5c\u51fa\u524d\u77bb\u6027\u9648\u8ff0\u5f53\u65e5\u4e4b\u540e\uff0c\u65e0\u8bba\u662f\u5426\u51fa\u73b0\u65b0\u8d44\u6599\u3001\u672a\u6765\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u51b5\uff0c\u6211\u4eec\u5e76\u65e0\u8d23\u4efb\u66f4\u65b0\u6216\u516c\u5f00\u4fee\u6539\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u53ca\u9884\u6599\u4e4b\u5916\u7684\u4e8b\u4ef6\u3002\u8bf7\u7ec6\u9605\u672c\u6587\uff0c\u5e76\u7406\u89e3\u6211\u4eec\u7684\u5b9e\u9645\u672a\u6765\u4e1a\u7ee9\u6216\u8868\u73b0\u53ef\u80fd\u4e0e\u9884\u671f\u6709\u91cd\u5927\u5dee\u5f02\u3002\u672c\u6587\u5185\u6240\u6709\u9648\u8ff0\u4e43\u672c\u6587\u7ae0\u520a\u53d1\u65e5\u671f\u4f5c\u51fa\uff0c\u53ef\u80fd\u56e0\u672a\u6765\u53d1\u5c55\u800c\u51fa\u73b0\u53d8\u52a8\u3002<\/p>\n

                <\/div>\n","protected":false},"excerpt":{"rendered":"

                \u4e2d\u56fd\u82cf\u5dde\u548c\u7f8e\u56fd\u9a6c\u91cc\u5170\u5dde\u7f57\u514b\u7ef4\u5c14\u5e022022\u5e749\u670821\u65e5 \/\u7f8e\u901a\u793e\/ — \u81f4\u529b\u4e8e\u5728\u80bf\u7624\u3001\u4e59\u809d\u53ca\u4e0e\u8870\u8001\u76f8\u5173\u75be\u75c5\u7b49\u6cbb\u7597\u9886\u57df\u5f00\u53d1\u521b\u65b0\u836f\u7269\u7684\u9886\u5148\u751f\u7269\u533b\u836f\u4f01\u4e1a-\u4e9a\u76db\u533b\u836f\uff086855.HK\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u6838\u5fc3\u54c1\u79cd\u5965\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff0c\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b®\uff09\u6cbb\u7597\u8010\u836f\u6162\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5\uff08CML\uff09\u7684I\u671f\u548cII\u671f\u4e34\u5e8a\u7814\u7a76\u7ed3\u679c\u5df2\u4e8e\u8fd1\u671f\u5728\u56fd\u9645\u8457\u540d\u80bf\u7624\u5b66\u672f\u671f\u520aJournal of Hematology\uff06Oncology\uff08\u4ee5\u4e0b\u7b80\u79f0\uff1aJHO\u671f\u520a\uff09\u4e0a\u6b63\u5f0f\u53d1\u8868\uff0c\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u5176\u5728CML\u60a3\u8005\u4e2d\u7684\u6301\u4e45\u7597\u6548\u548c\u5b89\u5168\u6027\u3002 JHO\u671f\u520a\u662f\u5168\u7403\u8840\u6db2\u5b66\u548c\u80bf\u7624\u5b66\u9886\u57df\u7684\u9886\u5148\u520a\u7269\uff0c\u8be5\u671f\u520a\u53d1\u8868\u7684\u9876\u7ea7\u7814\u7a76\u5168\u65b9\u4f4d\u6db5\u76d6\u4e86\u8840\u6db2\u5b66\u548c\u80bf\u7624\u5b66\u9886\u57df\uff0c\u5176\u5f71\u54cd\u56e0\u5b50\u4e3a23.168[1]\u3002\u6b64\u6b21\u53d1\u8868\u5728\u8be5\u671f\u520a\u4e0a\u7684\u7814\u7a76\u9898\u4e3aOlverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial[2]\u3002\u8010\u7acb\u514b®\u4e2d\u56fd\u4e34\u5e8a\u8bd5\u9a8c\u4e3b\u8981\u7814\u7a76\u8005\u3001\u5317\u4eac\u5927\u5b66\u8840\u6db2\u75c5\u7814\u7a76\u6240\u6240\u957f\u3001\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u8840\u6db2\u79d1\u4e3b\u4efb\u9ec4\u6653\u519b\u6559\u6388\u662f\u8be5\u6587\u7ae0\u7684\u901a\u8baf\u4f5c\u8005\uff1b\u8010\u7acb\u514b®\u4e2d\u56fd\u4e34\u5e8a\u8bd5\u9a8c\u4e3b\u8981\u7814\u7a76\u8005\u3001\u5317\u4eac\u5927\u5b66\u4eba\u6c11\u533b\u9662\u8840\u6db2\u79d1\u526f\u4e3b\u4efb\u6c5f\u5029\u6559\u6388\u662f\u8be5\u6587\u7ae0\u7684\u7b2c\u4e00\u4f5c\u8005\u3002 \u8be5\u7814\u7a76\u516c\u5e03\u4e86\u8010\u7acb\u514b®\u7528\u4e8e165\u4f8b\u524d\u671f\u63a5\u53d7\u8fc7\u591a\u7ebfTKI\u6cbb\u7597\u7684\u4e2d\u56fdCML\u60a3\u8005\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u3002\u53d7\u8bd5\u8005\u961f\u5217\u5305\u62ec\u4f34\u6709T315I\u7a81\u53d8\u7684TKI\u8010\u836fCML\u60a3\u8005\uff0c\u4e2d\u4f4d\u968f\u8bbf\u65f6\u95f4\u8fd13\u5e74\u3002\u6570\u636e\u663e\u793a\uff0c\u5728CML\u6162\u6027\u671f\uff08CP\uff09\u60a3\u8005\u4e2d\uff0c\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\u548c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\u76843\u5e74\u7d2f\u79ef\u53cd\u5e94\u7387\u5206\u522b\u4e3a79%\u548c56%\uff1b\u5728CML\u52a0\u901f\u671f\uff08AP\uff09\u60a3\u8005\u4e2d\uff0c\u4e3b\u8981\u7ec6\u80de\u9057\u4f20\u5b66\u53cd\u5e94\u548c\u4e3b\u8981\u5206\u5b50\u5b66\u53cd\u5e94\u76843\u5e74\u7d2f\u79ef\u53cd\u5e94\u7387\u5206\u522b\u4e3a47%\u548c45%\uff0c\u6b64\u5916\uff0c\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\uff0c\u7ec6\u80de\u9057\u4f20\u5b66\u548c\u5206\u5b50\u5b66\u53cd\u5e94\u7387\u4f1a\u8fdb\u4e00\u6b65\u589e\u52a0\u3002\u800c\u5728\u5b89\u5168\u6027\u65b9\u9762\uff0c\u5e38\u89c1\u975e\u8840\u6db2\u5b66\u4e0d\u826f\u4e8b\u4ef6\u4e3b\u8981\u4e3a\u76ae\u80a4\u8272\u7d20\u6c89\u7740\u3001\u9ad8\u7518\u6cb9\u4e09\u916f\u8840\u75c7\u7b49\uff0c\u5927\u591a\u4e3a1-2\u7ea7\uff1b\u8840\u6db2\u5b66\u4e0d\u826f\u4e8b\u4ef6\u5728\u6682\u65f6\u6682\u505c\u6cbb\u7597\u6216\u652f\u6301\u6cbb\u7597\u540e\u6d88\u9000\u3002\u4e0d\u826f\u4e8b\u4ef6\u591a\u4e3a\u53ef\u63a7\u5236\u548c\u53ef\u8010\u53d7\u3002\u7279\u522b\u662f\u968f\u7740\u6cbb\u7597\u65f6\u95f4\u7684\u5ef6\u957f\uff0c\u8840\u5c0f\u677f\u51cf\u5c11\u7b49\u526f\u4f5c\u7528\u6301\u7eed\u51cf\u5c11\u3002\u8fd9\u663e\u793a\u8010\u7acb\u514b®\u5728TKI\u8010\u836f\u7684CML-CP\u6216CML-AP\u60a3\u8005\u4e2d\u8010\u53d7\u826f\u597d\uff0c\u4e14\u7597\u6548\u7a33\u5b9a\u6301\u4e45\u3002\u6b64\u5916\uff0c\u8be5\u54c1\u79cd\u5bf9BCR-ABL1T315I\u7a81\u53d8\u4f53\u8868\u73b0\u51fa\u9ad8\u5ea6\u6d3b\u6027\uff0c\u5e76\u5728\u590d\u5408\u7a81\u53d8\u60a3\u8005\u4e2d\u5448\u73b0\u4ee4\u4eba\u9f13\u821e\u7684\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u800c\u8fd9\u90e8\u5206\u60a3\u8005\u76ee\u524d\u5c1a\u65e0\u6807\u51c6\u6cbb\u7597\u65b9\u6848\u3002 CML\u662f\u4e00\u79cd\u4e0e\u767d\u7ec6\u80de\u6709\u5173\u7684\u6076\u6027\u80bf\u7624\u3002\u968f\u7740\u9776\u5411BCR-ABL\u7684\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff08TKI\uff09\u7684\u4e0a\u5e02\uff0cCML\u7684\u6cbb\u7597\u65b9\u5f0f\u5f97\u4ee5\u9769\u65b0\u3002\u5c3d\u7ba1\u7b2c\u4e00\u4ee3\u548c\u7b2c\u4e8c\u4ee3TKI\u5bf9CML\u7684\u6cbb\u7597\u5177\u6709\u663e\u8457\u7684\u4e34\u5e8a\u6548\u76ca\uff0c\u4f46TKI\u8010\u836f\u4e00\u76f4\u662fCML\u6cbb\u7597\u7684\u4e3b\u8981\u6311\u6218\u3002BCR-ABL\u6fc0\u9176\u533a\u7a81\u53d8\u662fTKI\u8010\u836f\u7684\u91cd\u8981\u673a\u5236\u4e4b\u4e00\uff0c\u5176\u4e2dT315I\u7a81\u53d8\u662f\u5e38\u89c1\u7684\u8010\u836f\u7a81\u53d8\u7c7b\u578b\u4e4b\u4e00\uff0c\u5728\u8010\u836fCML\u4e2d\u7684\u53d1\u751f\u7387\u53ef\u8fbe25%\u5de6\u53f3\u3002\u4f34\u6709T315I\u7a81\u53d8\u7684\u6162\u7c92\u60a3\u8005\u5bf9\u76ee\u524d\u6240\u6709\u4e00\u4ee3\u3001\u4e8c\u4ee3BCR-ABL\u6291\u5236\u5242\u5747\u8010\u836f\u3002\u4e34\u5e8a\u4e0a\u5bf9\u53ef\u5b89\u5168\u6709\u6548\u6cbb\u7597T315I\u7a81\u53d8CML\u6162\u7c92\u60a3\u8005\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\u9700\u6c42\u5de8\u5927\u3002 \u8010\u7acb\u514b®\u662f\u4e9a\u76db\u533b\u836f\u7814\u53d1\u7684\u6f5c\u5728\u540c\u7c7b\u6700\u4f73\uff08Best-in-class\uff09\u65b0\u836f\uff0c\u4e3a\u56fd\u5bb6"\u91cd\u5927\u65b0\u836f\u521b\u5236"\u4e13\u9879\u652f\u6301\u54c1\u79cd\u3002\u4f5c\u4e3a\u4e2d\u56fd\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5242\uff0c\u8010\u7acb\u514b®\u7684\u51fa\u73b0\u6253\u7834\u4e86\u4e2d\u56fd\u643aT315I\u7a81\u53d8\u8010\u836fCML\u60a3\u8005\u957f\u671f\u65e0\u836f\u53ef\u533b\u7684\u56f0\u5c40\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b®\u5df2\u83b7\u4e2d\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08CSCO\uff09\u6307\u5357\u548c\u4e2d\u56fd\u6297\u764c\u534f\u4f1a\u300a\u4e2d\u56fd\u80bf\u7624\u6574\u5408\u8bca\u6cbb\u6307\u5357\uff08CACA\uff09\u300b\u63a8\u8350\uff0c\u6cbb\u7597\u4f34\u6709T315I\u7a81\u53d8\u7684\u65e2\u5f80TKI\u8010\u836f\u6162\u7c92\u60a3\u8005\uff08CACA\u6307\u5357\u4ea6\u63a8\u8350\u8be5\u54c1\u79cd\u7528\u4e8e\u6cbb\u7597\u63a5\u53d7\u8fc72\u79cd\u4ee5\u4e0aTKI\u8010\u836f\u6216\u4e0d\u8010\u53d7\u7684\u6162\u7c92\u60a3\u8005\uff09\u3002 \u800c\u5728\u5168\u7403\u5c42\u9762\uff0c\u5c3d\u7ba1\u6b64\u524d\u5df2\u6709\u53e6\u5916\u4e00\u6b3eBCR-ABL\u6291\u5236\u5242\u83b7\u6279\uff0c\u4f46\u56e0\u836f\u7269\u53ef\u53ca\u6027\u3001\u836f\u7269\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u7b49\u539f\u56e0\uff0c\u8010\u836fCML\u7684\u6cbb\u7597\u4ecd\u7136\u5b58\u5728\u672a\u88ab\u5b8c\u5168\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42\u3002\u6b63\u56e0\u5982\u6b64\uff0c\u8fd1\u5e74\u6765\u8be5\u836f\u7269\u7684\u4e34\u5e8a\u8fdb\u5c55\u4e0d\u65ad\u53d7\u5230\u5168\u7403\u8840\u6db2\u5b66\u754c\u7684\u5173\u6ce8\u3002\u81ea2018\u5e74\u8d77\uff0c\u8010\u7acb\u514b®\u7684\u4e34\u5e8a\u8fdb\u5c55\u8fde\u7eed\u56db\u5e74\u5165\u9009\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u53e3\u5934\u62a5\u544a\uff0c\u5e76\u8363\u83b72019 ASH\u5e74\u4f1a"\u6700\u4f73\u7814\u7a76"\u7684\u63d0\u540d\u3002\u76ee\u524d\uff0c\u8010\u7acb\u514b®\u5df2\u5728\u7f8e\u56fd\u8fdb\u5165Ib\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u7528\u4e8e\u6cbb\u7597\u8010\u836fCML\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b®\u5171\u83b71\u9879\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u5feb\u901f\u901a\u9053\u8d44\u683c\u30013\u9879FDA\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u548c1\u9879\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08EMA\uff09\u7684\u6b27\u76df\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u3002 \u9ec4\u6653\u519b\u6559\u6388\u8868\u793a\uff1a"\u4f5c\u4e3a\u5728\u8840\u6db2\u80bf\u7624\u9886\u57df\u94bb\u7814\u8d85\u8fc730\u5e74\u7684\u4e2d\u56fd\u4e34\u5e8a\u533b\u751f\uff0c\u4e5f\u4f5c\u4e3a\u8010\u7acb\u514b®\u4e34\u5e8a\u8bd5\u9a8c\u7684\u4e3b\u8981\u7814\u7a76\u8005\uff0c\u6211\u5f88\u9ad8\u5174\u770b\u5230\u8010\u7acb\u514b®\u8fd9\u6b3e\u521b\u65b0\u836f\u7269\u7684\u4e34\u5e8a\u8fdb\u5c55\u5728JHO\u671f\u520a\u4e0a\u53d1\u8868\uff0c\u8fd9\u518d\u6b21\u8bc1\u660e\u8010\u7acb\u514b®\u8fd9\u4e00\u4e2d\u56fd\u539f\u521b\u7684\u4ea7\u54c1\u6709\u671b\u4e3a\u5168\u7403CML\u6cbb\u7597\u9886\u57df\u5e26\u53bb\u4e2d\u56fd\u65b9\u6848\u3002\u5e0c\u671b\u6709\u8d8a\u6765\u8d8a\u591a\u50cf\u8010\u7acb\u514b®\u8fd9\u6837\u7684\u672c\u571f\u521b\u65b0\u836f\u6d8c\u73b0\uff0c\u7ed9\u5230\u66f4\u591a\u4e2d\u56fd\u4e34\u5e8a\u533b\u751f\u673a\u4f1a\u4e3b\u5bfc\u65b0\u836f\u7684\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5728\u8fd9\u4e00\u8fc7\u7a0b\u4e2d\u79ef\u7d2f\u4e2d\u56fd\u6570\u636e\u548c\u7ecf\u9a8c\u5e76\u8f6c\u5316\u4e3a\u5177\u6709\u56fd\u9645\u524d\u77bb\u6027\u7684\u5faa\u8bc1\u533b\u5b66\u6210\u679c\u5bf9\u5916\u53d1\u8868\uff0c\u6700\u7ec8\u63d0\u5347\u4e2d\u56fd\u5728\u5168\u7403\u7684\u56fd\u9645\u5b66\u672f\u5f71\u54cd\u529b\u3002" \u6c5f\u5029\u6559\u6388\u8868\u793a\uff1a"\u76ee\u524d\uff0cCML\u60a3\u8005\u4e2d\u670920-30%\u4f1a\u5bf9\u73b0\u6709TKI\u8010\u836f\u6216\u4e0d\u8010\u53d7\uff0c\u4ece\u800c\u5bfc\u81f4\u75be\u75c5\u8fdb\u5c55\uff0c\u5176\u4e2d\uff0c\u8bb8\u591a\u60a3\u8005\u5728\u8f6c\u6362\u7528\u7b2c\u4e8c\u79cd\u6216\u7b2c\u4e09\u79cdTKI\u540e\u4f1a\u56e0\u65b0\u7684\u7a81\u53d8\u6216\u5176\u4ed6\u5e76\u53d1\u75c7\u800c\u672a\u80fd\u8fbe\u5230\u9884\u671f\u91cc\u7a0b\u7891\u76ee\u6807\u5bfc\u81f4\u6cbb\u7597\u5931\u8d25\u3002\u53ef\u4ee5\u8bf4\uff0cTKI\u8010\u836f\u662fCML\u6cbb\u7597\u5168\u7403\u6027\u7684\u6311\u6218\u3002\u6b64\u6b21\u53d1\u8868\u5728JHO\u671f\u520a\u4e0a\u7684\u6570\u636e\u663e\u793a\uff0c\u8010\u7acb\u514b®\u5bf9\u4e8eCML\u5177\u6709\u826f\u597d\u7684\u7597\u6548\u5e76\u80fd\u591f\u6709\u6548\u514b\u670dT315I\u7a81\u53d8\uff0c\u540c\u65f6\u5bf9\u76ee\u524d\u5c1a\u65e0\u6709\u6548\u6cbb\u7597\u65b9\u6848\u7684BCR-ABL\u6fc0\u9176\u7ed3\u6784\u57df\u590d\u5408\u7a81\u53d8\u663e\u793a\u51fa\u4ee4\u4eba\u9f13\u821e\u7684\u4e34\u5e8a\u6d3b\u6027\u3002\u8fd9\u4ee3\u8868\u8010\u7acb\u514b®\u662f\u4e00\u79cd\u6781\u5bcc\u6f5c\u529b\u7684CML\u6cbb\u7597\u836f\u7269\u3002" \u4e9a\u76db\u533b\u836f\u9996\u5e2d\u533b\u5b66\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a"\u8010\u7acb\u514b®\u662f\u5177\u6709"best-in-class"\u6f5c\u529b\u7684\u539f\u521b1\u7c7b\u65b0\u836f\uff0c\u5176\u4e34\u5e8a\u5f00\u53d1\u662f\u4e9a\u76db\u533b\u836f\u5168\u7403\u521b\u65b0\u6218\u7565\u7684\u8df5\u884c\u3002\u6b64\u6b21\u8010\u7acb\u514b®\u7684I\/II\u671f\u4e34\u5e8a\u8fdb\u5c55\u8363\u767bJournal of Hematology\uff06Oncology\uff0c\u65e2\u4f53\u73b0\u4e86\u8be5\u54c1\u79cd\u5728\u5168\u7403\u8010\u836fCML\u9886\u57df\u7684\u6cbb\u7597\u6f5c\u529b\uff0c\u66f4\u4ee3\u8868\u516c\u53f8\u7684\u5168\u7403\u521b\u65b0\u6218\u7565\u518d\u65a9\u4f73\u7ee9\u3002\u6211\u4eec\u8feb\u5207\u5730\u671f\u5f85\u8010\u7acb\u514b®\u80fd\u4ee5\u4e2d\u56fd\u4e3a\u8d77\u70b9\uff0c\u4e3a\u5168\u7403\u8010\u836fCML\u60a3\u8005\u5e26\u53bb\u4e00\u79cd\u7597\u6548\u786e\u5207\u3001\u5b89\u5168\u6027\u66f4\u4f73\u7684\u6cbb\u7597\u65b9\u6848\u3002\u672a\u6765\uff0c\u6211\u4eec\u5c06\u7ee7\u7eed\u575a\u5b88\u2018\u89e3\u51b3\u4e2d\u56fd\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6ee1\u8db3\u7684\u4e34\u5e8a\u9700\u6c42’\u7684\u4f7f\u547d\uff0c\u52a0\u5feb\u516c\u53f8\u5728\u7814\u54c1\u79cd\u5728\u5168\u7403\u5c42\u9762\u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u65e9\u65e5\u9020\u798f\u60a3\u8005\u3002" \u6b64\u6b21\u8010\u7acb\u514b®\u767b\u4e0aJournal of Hematology & Oncology\u7684\u7814\u7a76\u8981\u70b9\u5982\u4e0b\uff1a Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":80861,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-80858","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/80858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=80858"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/80858\/revisions"}],"predecessor-version":[{"id":80860,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/80858\/revisions\/80860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/80861"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=80858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=80858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=80858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}